http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-053133-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0bf7b82e0f0ef387acf43f2ddd705ccf |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-255 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-423 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-255 |
| filingDate | 2006-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fc19184c43eae47d24bb0c0a828c88d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7c22b3f43639fb24068877e11761aed |
| publicationDate | 2007-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-053133-A1 |
| titleOfInvention | METHOD TO TREAT OBESITY |
| abstract | Methods to treat obesity and minimize the metabolic risk factors associated with it using, for example, zonisamide or other weight loss promoter anticonvulsant, either alone or in combination with bupropion or metabolites of the same or other compound capable of increasing the activity of norepinephrine and / or dopamine by inhibition of uptake or by another mechanism. Claim 11: A composition, characterized in that it comprises a bupropion metabolite and at least one weight loss promoter anticonvulsant of formula (3), wherein R1 is an H or halogen atom, R2 and R3 are the same or different and each one is H or a C1-3 alkyl, and one between X and Y is an atom of C and the other is an atom of N, provided that the group -CH2SO2NR2R3 is attached to a C atom of either X and Y , or a salt of an alkali metal thereof, in an amount sufficient to effect said treatment. Claim 17: The use of a bupropion metabolite and a weight loss promoter anticonvulsant, characterized in that it is for preparing a medicament for the treatment of obesity in a mammal, wherein said weight loss promoting anticonvulsant is a compound of the formula (3), where R1 is an H or halogen atom, R2 and R3 are the same or different and each is H or a C1-3 alkyl, and one between X and Y is a C atom and the other is an N atom, provided that the group -CH2SO2NR2R3 is attached to a C atom of either X and Y, or a salt of an alkali metal thereof. |
| priorityDate | 2005-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.